Showing 1 - 9 results of 9 for search 'Anastasios Stathis', query time: 0.03s Refine Results
  1. 1
    Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma

    Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma by Maria Cristina Pirosa, Anastasios Stathis, Emanuele Zucca

    Published 2024-12-01
    Get full text
    Article
  2. 2
    Adverse Event Reporting with Immune Checkpoint Inhibitors in Older Patients: Age Subgroup Disproportionality Analysis in VigiBase

    Adverse Event Reporting with Immune Checkpoint Inhibitors in Older Patients: Age Subgroup Disproportionality Analysis in VigiBase by Roberta Noseda, Giulia Bonaldo, Domenico Motola, Anastasios Stathis, Alessandro Ceschi

    Published 2021-03-01
    Get full text
    Article
  3. 3
    Prognostic implication of PD-L1 in early-stage non-small cell lung cancer: a retrospective single-centre study

    Prognostic implication of PD-L1 in early-stage non-small cell lung cancer: a retrospective single-centre study by Elona Cekani, Carolina Martorelli, Francesco Martucci, Miriam Patella, Stefano Cafarotti, Antonio Valenti, Stefania Freguia, Francesca Molinari, Patrizia Froesch, Milo Frattini, Anastasios Stathis, Luciano Wannesson

    Published 2023-09-01
    Get full text
    Article
  4. 4
    The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type

    The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type by Chiara Tarantelli, Eleonora Cannas, Hillarie Ekeh, Carmelo Moscatello, Eugenio Gaudio, Luciano Cascione, Sara Napoli, Cesare Rech, Andrea Testa, Chiara Maniaci, Andrea Rinaldi, Emanuele Zucca, Anastasios Stathis, Alessio Ciulli, Francesco Bertoni

    Published 2021-12-01
    Get full text
    Article
  5. 5
    Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma

    Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma by Filippo Spriano, Giulio Sartori, Chiara Tarantelli, Marilia Barreca, Gaetanina Golino, Andrea Rinaldi, Sara Napoli, Michele Mascia, Lorenzo Scalise, Alberto J. Arribas, Luciano Cascione, Emanuele Zucca, Anastasios Stathis, Eugenio Gaudio, Francesco Bertoni

    Published 2022-08-01
    Get full text
    Article
  6. 6
    The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax

    The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax by Chiara Tarantelli, Eugenio Gaudio, Petra Hillmann, Filippo Spriano, Giulio Sartori, Luca Aresu, Luciano Cascione, Denise Rageot, Ivo Kwee, Florent Beaufils, Emanuele Zucca, Anastasios Stathis, Matthias P. Wymann, Vladimir Cmiljanovic, Doriano Fabbro, Francesco Bertoni

    Published 2019-06-01
    Get full text
    Article
  7. 7
    P1132: LONG-TERM RESPONSES WITH LONCASTUXIMAB TESIRINE: UPDATED RESULTS FROM LOTIS-2, THE PIVOTAL PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

    P1132: LONG-TERM RESPONSES WITH LONCASTUXIMAB TESIRINE: UPDATED RESULTS FROM LOTIS-2, THE PIVOTAL PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA by Paolo F Caimi, Weiyun Z Ai, Juan Pablo Alderuccio, Kirit M Ardeshna, Mehdi Hamadani, Brian Hess, Brad S Kahl, John Radford, Melhem Solh, Anastasios Stathis, Pier Luigi Zinzani, Ying Wang, Yajuan Qin, Luqiang Wang, Cindy Xu, Carmelo Carlo-Stella

    Published 2023-08-01
    Get full text
    Article
  8. 8
    Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA)

    Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA) by Markus Joerger, Yannis Metaxas, Khalil Zaman, Olivier Michielin, Nicolas Mach, Adrienne Bettini, Andreas M. Schmitt, Nathan Cantoni, Clemens B. Caspar, Sonja Stettler, Roma Malval, Miklos Pless, Christian Britschgi, Christoph Renner, Dieter Koeberle, Jessica D. Schulz, Christoph Kopp, Stefanie Hayoz, Anastasios Stathis, Roger von Moos

    Published 2022-04-01
    Get full text
    Article
  9. 9
    A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma

    A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma by Graham P. Collins, Toby A. Eyre, Debora Schmitz-Rohmer, William Townsend, Rakesh Popat, Lisa Giulino-Roth, Paul A. Fields, Fatime Krasniqi, Carole Soussain, Anastasios Stathis, Nebojsa Andjelkovic, David Cunningham, Danijela Mandic, Sinisa Radulovic, Ivan Tijanic, Netanel A. Horowitz, Sabira Kurtovic, Elisabeth Schorb, Christian Schmidt, Saša Dimitrijević, Martin Dreyling

    Published 2021-11-01
    Get full text
    Article

Search Tools: